| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $13,322,539 | 8 | 42 |
Sells | $601,462 | 11 | 58 |
| Lynx1 Capital Management LP | 10 percent owner | 8 | $13.32M | 0 | $0 | $13.32M |
| SUMER JACQUELYN L | Chief Legal Officer | 0 | $0 | 2 | $71,768 | $-71,768 |
| Jones Jeffrey Alan | Chief Medical Officer | 0 | $0 | 2 | $94,605 | $-94,605 |
| AHMED NADIM | President and CEO | 0 | $0 | 2 | $206,580 | $-206,580 |
| Michaelson Jennifer | Chief Scientific Officer | 0 | $0 | 5 | $228,508 | $-228,508 |
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Over the last 12 months, insiders at Cullinan Therapeutics, Inc. have bought $13.32M and sold $601,462 worth of Cullinan Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cullinan Therapeutics, Inc. have bought $17.32M and sold $7.1M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lynx1 Capital Management LP (10 percent owner) — $13.32M.
The last purchase of 165,667 shares for transaction amount of $1.39M was made by Lynx1 Capital Management LP (10 percent owner) on 2025‑10‑28.
| 2025-11-24 | Sale | Michaelson Jennifer | Chief Scientific Officer | 4,000 0.0088% | $12.30 | $49,200 | -11.71% | |
| 2025-10-28 | Lynx1 Capital Management LP | 10 percent owner | 165,667 0.3048% | $8.40 | $1.39M | +1.23% | ||
| 2025-10-17 | Lynx1 Capital Management LP | 10 percent owner | 32,217 0.0544% | $7.84 | $252,565 | +7.89% | ||
| 2025-10-16 | Lynx1 Capital Management LP | 10 percent owner | 150,000 0.2573% | $8.86 | $1.33M | -3.52% | ||
| 2025-10-15 | Lynx1 Capital Management LP | 10 percent owner | 51,500 0.0802% | $7.94 | $409,049 | -1.74% | ||
| 2025-10-14 | Lynx1 Capital Management LP | 10 percent owner | 15,032 0.0249% | $7.59 | $114,048 | +9.63% | ||
| 2025-10-10 | Lynx1 Capital Management LP | 10 percent owner | 277,298 0.467% | $7.36 | $2.04M | +13.95% | ||
| 2025-10-09 | Lynx1 Capital Management LP | 10 percent owner | 626,043 1.0065% | $6.70 | $4.19M | +18.94% | ||
| 2025-10-08 | Lynx1 Capital Management LP | 10 percent owner | 556,300 0.9432% | $6.46 | $3.59M | +28.29% | ||
| 2025-02-25 | Sale | AHMED NADIM | President and CEO | 12,529 0.0203% | $8.53 | $106,872 | -8.59% | |
| 2025-02-25 | Sale | Jones Jeffrey Alan | Chief Medical Officer | 4,895 0.0079% | $8.53 | $41,754 | -8.59% | |
| 2025-02-25 | Sale | Michaelson Jennifer | Chief Scientific Officer | 3,756 0.0061% | $8.53 | $32,039 | -8.59% | |
| 2025-02-25 | Sale | SUMER JACQUELYN L | Chief Legal Officer | 3,756 0.0061% | $8.53 | $32,039 | -8.59% | |
| 2025-01-06 | Sale | Michaelson Jennifer | Chief Scientific Officer | 4,000 0.0072% | $12.51 | $50,040 | -32.60% | |
| 2024-12-24 | Sale | AHMED NADIM | President and CEO | 8,400 0.014% | $11.87 | $99,708 | -34.56% | |
| 2024-12-18 | Sale | Jones Jeffrey Alan | Chief Medical Officer | 4,632 0.0085% | $11.41 | $52,851 | -25.07% | |
| 2024-12-18 | Sale | Michaelson Jennifer | Chief Scientific Officer | 4,693 0.0087% | $11.41 | $53,547 | -25.07% | |
| 2024-12-18 | Sale | SUMER JACQUELYN L | Chief Legal Officer | 3,482 0.0064% | $11.41 | $39,730 | -25.07% | |
| 2024-12-12 | Sale | Michaelson Jennifer | Chief Scientific Officer | 3,489 0.0062% | $12.52 | $43,682 | -33.65% | |
| 2024-11-05 | Sale | Michaelson Jennifer | Chief Scientific Officer | 8,000 0.0134% | $15.64 | $125,120 | -48.94% |
| Lynx1 Capital Management LP | 10 percent owner | 8963500 15.1729% | $94.83M | 8 | 0 | |
| AHMED NADIM | President and CEO | 430621 0.7289% | $4.56M | 1 | 7 | <0.0001% |
| Jones Jeffrey Alan | Chief Medical Officer | 174164 0.2948% | $1.84M | 0 | 8 | |
| Michaelson Jennifer | Chief Scientific Officer | 138004 0.2336% | $1.46M | 0 | 28 | |
| SUMER JACQUELYN L | Chief Legal Officer | 136895 0.2317% | $1.45M | 0 | 8 | |
| UBS Oncology Impact Fund L.P. | 10 percent owner | 7648268 12.9466% | $80.92M | 1 | 18 | <0.0001% |
| LAMPERT MARK N | 4058854 6.8706% | $42.94M | 3 | 0 | +15.29% | |
| Jovan-Embiricos Morana | 1281952 2.17% | $13.56M | 1 | 3 | <0.0001% | |
| Hughes Owen | President and CEO | 506226 0.8569% | $5.36M | 1 | 0 | <0.0001% |
| GADICKE ANSBERT | 244551 0.414% | $2.59M | 1 | 18 | <0.0001% | |
| Savill Corrine | Chief Business Officer | 165990 0.281% | $1.76M | 0 | 6 | |
| Trigilio Jeffrey | Chief Financial Officer | 83919 0.1421% | $887,863.02 | 1 | 12 | <0.0001% |
| Zawel Leigh | See Remarks | 37285 0.0631% | $394,475.30 | 0 | 7 | |
| Baeuerle Patrick | See Remarks | 0 0% | $0 | 0 | 2 |
| Increased Positions | 81 | +50.94% | 5M | +7.6% |
| Decreased Positions | 67 | -42.14% | 7M | -10.41% |
| New Positions | 26 | New | 943,872 | New |
| Sold Out Positions | 27 | Sold Out | 3M | Sold Out |
| Total Postitions | 173 | +8.81% | 62M | -2.81% |
| Mpm Bioimpact Llc | $86,961.00 | 12.96% | 7.65M | 0 | 0% | 2025-09-30 |
| Lynx1 Capital Management Lp | $65,560.00 | 9.77% | 5.77M | +1M | +31.02% | 2025-09-30 |
| Bvf Inc/Il | $65,385.00 | 9.75% | 5.75M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $47,412.00 | 7.07% | 4.17M | -47,971 | -1.14% | 2025-09-30 |
| Vanguard Group Inc | $33,466.00 | 4.99% | 2.94M | -76,775 | -2.54% | 2025-09-30 |
| Deerfield Management Company, L.P. | $33,280.00 | 4.96% | 2.93M | -928,539 | -24.08% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $28,550.00 | 4.26% | 2.51M | +125,000 | +5.24% | 2025-09-30 |
| Kynam Capital Management, Lp | $26,176.00 | 3.9% | 2.3M | +206,174 | +9.84% | 2025-09-30 |
| Citadel Advisors Llc | $22,563.00 | 3.36% | 1.98M | -629,286 | -24.08% | 2025-09-30 |
| Orbimed Advisors Llc | $21,874.00 | 3.26% | 1.92M | 0 | 0% | 2025-09-30 |